Somatostatin Receptor 5 antibody | sstr5
Mouse anti Human Somatostatin Receptor 5 antibody, clone sstr5 recognizes human somatostatin receptor 5 (SS-5-R), a 364 amino acid multi pass transmembrane glycoprotein receptor for Somatostatin-28 and to a lesser extent somatostatin-14. (SST) is a peptide hormone with wide ranging inhibitory effects on hormone secretion and cell proliferation. It is produced as a large preproSST precursor molecule that is cleaved to yield one of two active forms of the peptide: a 14 amino acid peptide (SST-14), or a 28 amino acid peptide (SST-28). The inhibitory effects of SST on hormone release and cell growth have made them candidates for the treatment of cancer and neuroendocrine disorders. Natural SSTs have very short half-lives, which led to the development of more stable synthetic derivatives, such as octreotide and lanreotide, both in common clinical use.
The effects of SST are mediated via five distinct SST receptors (SSTRs). The receptors have similar affinities for natural SST-14 and SST-28, but there are marked differences in affinities towards the synthetic analogues. Somatostatin receptors are expressed by various tissues, notably neuronal, endocrine, gastrointestinal and immune cells, as well as certain tumours, with tumours often expressing more than one subtype in different combinations.
Mouse anti Human Somatostatin Receptor 5 antibody, clone sstr5 specifically recognises SSTR type 5, but none of the other SSTR subtypes. Bio-Rad also has antibodies to SSTR subtypes 1, 3 and 4 (MCA5924, MCA5921, MCA5922) available.
The effects of SST are mediated via five distinct SST receptors (SSTRs). The receptors have similar affinities for natural SST-14 and SST-28, but there are marked differences in affinities towards the synthetic analogues. Somatostatin receptors are expressed by various tissues, notably neuronal, endocrine, gastrointestinal and immune cells, as well as certain tumours, with tumours often expressing more than one subtype in different combinations.
Mouse anti Human Somatostatin Receptor 5 antibody, clone sstr5 specifically recognises SSTR type 5, but none of the other SSTR subtypes. Bio-Rad also has antibodies to SSTR subtypes 1, 3 and 4 (MCA5924, MCA5921, MCA5922) available.
Product Details
- Target Species
- Human
- Product Form
- Purified IgG - liquid
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Carrier Free
- Yes
- Immunogen
- Synthetic peptide, sequence CAHRAAANGLMQTSKL.
- Approx. Protein Concentrations
- IgG concentration 1mg/ml
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
More Information
- UniProt
- P35346
- Entrez Gene
- SSTR5
- GO Terms
- GO:0004994 somatostatin receptor activity
- GO:0005887 integral to plasma membrane
- GO:0008285 negative regulation of cell proliferation
- Regulatory
- For research purposes only
Applications of Somatostatin Receptor 5 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Immunohistology - Paraffin | 1/100 | 1/250 | |
| Western Blotting |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Histology Positive Control Tissue
- Human pancreas
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Product Specific References
References for Somatostatin Receptor 5 antibody
-
Schmid, H.A. et al. (2012) Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors.
Neuroendocrinology. 95 (3): 232-47.
